Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368980 | 0.81 | LMNA (0.40) | KDR | |
| SCHEMBL4865898 | 0.77 | PTGS2 (0.33) | — | |
| SCHEMBL4862847 | 0.74 | KCNA5 (0.48) | — | |
| SCHEMBL4864904 | 0.73 | STK4 (0.38) | — | |
| SCHEMBL3384906 | 0.70 | LMNA (0.39) | KDR | |
| SCHEMBL2368941 | 0.69 | LMNA (0.43) | KDR | |
| SCHEMBL3383431 | 0.62 | ALDH1A1 (0.44) | KDR | |
| SCHEMBL3381246 | 0.60 | LMNA (0.43) | KDR | |
| SCHEMBL2369259 | 0.60 | LMNA (0.41) | KDR | |
| SCHEMBL3387889 | 0.60 | LMNA (0.50) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456187-B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION LIMITED (GB) | 2008-11-25 | — | — | US | claimed |
| US-7456187-B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION LIMITED (GB) | 2008-11-25 | — | — | US | disclosed |
| EP-1758909-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121149-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION DISCOVERY LTD. (GB) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | KCNH3, HCN4, KCNH2 | KDR 1617/4885SQOR 866/4885TLR7 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.